ARS Pharmaceuticals, Inc. (SPRY)
NASDAQ: SPRY · Real-Time Price · USD
9.28
-0.06 (-0.64%)
At close: Feb 27, 2026, 4:00 PM EST
9.29
+0.01 (0.11%)
After-hours: Feb 27, 2026, 5:17 PM EST

ARS Pharmaceuticals Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2024FY 2023FY 2022FY 2021FY 2020
Period Ending
Feb '26 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
9171,025526800--
Market Cap Growth
-18.84%94.90%-34.23%---
Enterprise Value
799821284839--
Last Close Price
9.2810.555.488.53--
PE Ratio
-128.20----
PS Ratio
6.4311.5017535.50607.80--
PB Ratio
6.213.992.282.93--
P/TBV Ratio
6.914.122.292.93--
P/FCF Ratio
-78.96----
P/OCF Ratio
-75.68----
EV/Sales Ratio
5.609.219483.00637.20--
EV/FCF Ratio
-63.20----
Debt / Equity Ratio
1.150.270.000.000.201.40
Debt / FCF Ratio
-5.35---1.10
Net Debt / Equity Ratio
-0.80-0.95-0.99-1.00-1.14-2.02
Net Debt / EBITDA Ratio
1.3281.423.387.962.6531.32
Net Debt / FCF Ratio
1.38-18.843.846.802.90-1.60
Asset Turnover
0.480.3100.010.13-
Quick Ratio
6.4113.7995.8050.597.343.03
Current Ratio
6.6614.2696.9251.017.423.21
Return on Equity (ROE)
-45.92%3.28%-21.59%-21.84%-77.93%-
Return on Assets (ROA)
-19.22%-0.66%-16.40%-12.56%-27.68%-
Return on Invested Capital (ROIC)
-329.76%-40.01%-8134.94%---
Return on Capital Employed (ROCE)
-28.20%-0.90%-29.30%-12.50%-36.50%-2.60%
Earnings Yield
-8.73%0.78%-10.33%-4.34%--
FCF Yield
-9.38%1.27%-11.30%-5.04%--
Buyback Yield / Dilution
-1.59%-7.54%-138.30%-38.39%-42.81%-
Updated Nov 10, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q